Clinical Development lead at Bayer, Honorary Associate Professor at University of Birmingham
This must be the first approval in treatment refractory sclc for decades. It’s exciting to have a therapy against a novel target and in a disease that has such a poor prognosis overall. The duration of RR will be interesting to see in the RWE/ population
🚨 🥁🥁🥁New FDA Approval 👉🏼Today the US FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy @FDAOncology #SCLC 🎯 ⭐️Tarlatamab = bispecific T-cell engager (BiTE), a two-armed drug that simultaneously latches onto tumor cells and T cells, bringing them close together and helping the T cells recognize and destroy cancer cells https://lnkd.in/eTXAdS85